Group 1 - The company, Kanghui Pharmaceutical, announced a change in its stock abbreviation from "Kanghui Pharmaceutical" to "Kanghui Co., Ltd." This change aims to provide a clearer and more concise representation of the company in the market [1] - The new abbreviation retains the core brand identifier "Kanghui" while adding "Co., Ltd." to help investors better understand the company's development positioning [1] - This adjustment is expected to assist investors in accurately grasping the company's core value and development direction [1]

人民财讯9月16日电，康惠制药（603139）9月16日晚间公告，公司拟将证券简称由"康惠制药"变更 为"康惠股份"。 ...

智通财经APP讯，康惠制药(603139.SH)发布公告，根据公司长期发展规划，公司拟将证券简称由"康惠 制药"变更为"康惠股份"，新证券简称简洁清晰，在保留"康惠"这一核心品牌标识的同时，新增"股 份"二字有助于市场更直观理解公司发展定位，有助于投资者准确把握公司核心价值与发展方向。 ...

Core Points - On September 10, 2025, Kanghui Pharmaceutical announced that its shareholder, Shanghai Chuangxiangying Enterprise Management Partnership, holding more than 5% of the company's shares, pledged 1,997,600 shares [1] Group 1 - The pledge registration date was September 9, 2025 [1]

Group 1 - The core point of the article is that Kanghui Pharmaceutical announced significant shareholding and pledge details from a major shareholder, along with its revenue composition for the first half of 2025 [1] Group 2 - Kanghui Pharmaceutical's major shareholder, Shanghai Chuangxiangying Enterprise Management Partnership, holds approximately 5.99 million shares, accounting for 6% of the total share capital [1] - As of the announcement date, Chuangxiangying has pledged about 4 million shares, which is 66.67% of its holdings and 4% of the total share capital [1] - For the first half of 2025, Kanghui Pharmaceutical's revenue composition is as follows: 60.68% from pharmaceutical manufacturing, 36.79% from pharmaceutical distribution, and 2.53% from other businesses [1] - The current market capitalization of Kanghui Pharmaceutical is 2.4 billion yuan [1]

2025 年 9 月 10 日，公司接到创响盈通知，获悉其将所持有的公司 1,997,600 股股份办理了质押，质押登记日为 2025 年 9 月 9 日，具体情况如下： 证券代码：603139 证券简称：康惠制药 公告编号：2025-059 陕西康惠制药股份有限公司 关于持股 5%以上股东部分股权质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 陕西康惠制药股份有限公司（以下简称"公司"）持股 5%以上股东上海 创响盈企业管理合伙企业（有限合伙）（以下简称"创响盈"）持有公司股份 5,992,800 股，占公司总股本的 6%。 创响盈本次质押公司股份 1,997,600 股，占其持有公司股份的 33.33%， 占公司总股本的 2%。截至本公告披露日，创响盈累计质押公司股份 3,995,200 股，占其持有公司股份的 66.67%，占公司总股本的 4%。 2025 年 9 月 11 日 | | | | 是否为 | 是 | | | | | | | | --- | --- | --- | --- | -- ...

Core Viewpoint - The announcement from Kanghui Pharmaceutical indicates that a major shareholder, Chuangxiangying, has pledged 1.9976 million shares, which represents 33.33% of its holdings and 2% of the company's total share capital. The purpose of the pledge is to supplement working capital [1] Summary by Categories Shareholder Pledge - Chuangxiangying has pledged a total of 1.9976 million shares, accounting for 33.33% of its holdings and 2% of the total share capital of the company [1] - As of the announcement date, Chuangxiangying has cumulatively pledged 3.9952 million shares, which is 66.67% of its holdings and 4% of the company's total share capital [1] Financing Purpose - The funds raised from the share pledge will be used to supplement the company's working capital [1]

Core Points - The company has changed its official email address for investor communication from irsxkh@163.com to ir@sxkh.com [1] - The new email address is effective immediately from the date of the announcement, while the old email address will be deactivated [1] - Other contact information, including the office address and phone number, remains unchanged [1] Summary by Sections - **Email Change**: The company has updated its electronic communication channel for investors [1] - **Effective Date**: The new email address is officially in use from the announcement date, with the old address being phased out [1] - **Contact Information**: All other contact details, such as office address and phone number, will stay the same [1]

Core Points - Kanghui Pharmaceutical (603139) announced a change in its official email address to ir@sxkh.com due to actual work needs [1]

证券代码：603139 证券简称：康惠制药 公告编号：2025-058 陕西康惠制药股份有限公司 关于变更公司电子邮箱的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 变更前的公司电子邮箱：irsxkh@163.com 变更后的公司电子邮箱：ir@sxkh.com 除上述变更外，公司办公地址、联系电话等其他联系方式保持不变。变更后 的电子邮箱自本公告披露之日起正式启用，原邮箱地址同步停用，敬请广大投资 者注意。由此给投资者带来的不便，敬请谅解。欢迎广大投资者通过新的电子邮 箱与公司沟通交流。 特此公告。 陕西康惠制药股份有限公司董事会 2025 年 9 月 10 日 1 陕西康惠制药股份有限公司（以下简称"公司"）根据实际工作需要，对公 司电子邮箱进行变更，具体情况如下： ...